Home > Resources > Company Profiles > Genentech Inc

Genentech Inc (DNA)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Enter the text you see in the image *

Letters are not case-sensitive, disregard spaces.

Try a New One

This helps us prevent automated registrations and spamming.

Email Confirmation

David A. Ebersman , Executive VP/CFO

www.gene.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A biotechnology company which discovers, develops and manufactures pharmaceutical products to treat patients with medical needs.

Portfolio Articles

Genes 'R' Us: The New Dot-Coms?
DNA tests for everything from diseases to ancestry are proliferating as a nascent industry tries to spark a revolution. Is this déjà vu all over again?
Mar 05 2008
Welcome to the Future
With a little help from Google, secretive Silicon Calley startup 23andMe is betting you’ll want to web-surf your own DNA. But is the science ready?

Oct 15 2007

See more news on this company

News Feeds

Closing Glance: Biotechnology AP
Jul 08 2008
Opening Glance: Biotechnology AP
Jul 08 2008
FDA clears Invitrogen breast cancer test AP
Jul 08 2008
Analysts: Key Genentech drug could top 2Q forecast AP
Jun 30 2008
Movers roundup: Popular, Genentech AP
Jun 30 2008
OSI shares rise on Weisel "Overweight" rating AP
Jun 27 2008
Sector Snap: Biotech _ large-cap or small-cap? AP
Jun 24 2008
Ahead of the Bell: Biotechnology companies AP
Jun 19 2008
Seattle Genetics gets milestone payment AP
Jun 18 2008
Roche will pay up to $774 million for cancer drug AP
Jun 18 2008

Press Releases

Bio-Pharma Launch Value Maximized Through New Product Commercialization Excellence Jul-03-2008, 03:45PM EDT
Zacks.com featured expert Kevin Matras highlights: Genentech, DaVita and Somanetics Jul-03-2008, 09:51AM EDT
VLST Corporation Appoints Internationally Recognized Researcher Paul J. Carter, Ph.D. as Chief Scientific Officer Jul-02-2008, 08:00AM EDT
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies Jun-30-2008, 12:47PM EDT
Seven Summits Research Releases Comments on DNA, PCLN, TWX, SBUX, and ENER Jun-30-2008, 10:41AM EDT

News From Around the Web

News

Mad Mail: Don't be Scared, Ring the Register! (CNBC)

Jul 09 2008
Biotechnology stocks close higher as Wall Street forecasts positive 2nd - quarter earnings (Canadian Business Online)

Jul 08 2008
New York Times Examines Benefits, Costs Of Cancer Drug Avastin (Medical News Today)

Jul 08 2008
Opening Glance: Biotechnology (Boston Globe)

Jul 08 2008
Biotech Stocks: Second-Half '08 Preview (The Street)

Jul 08 2008
Genentech shares fall after arthritis patient's death in trial (San Jose Mercury News)

Jul 08 2008
Closing Glance: Biotechnology ends mixed (Boston Globe)

Jul 07 2008
Genentech's Avasitin Price Is Unsustainable (SeekingAlpha)

Jul 07 2008
San Mateo County owes Genentech $20 million for property tax glitch (San Jose Mercury News)

Jul 06 2008

Blogs

Option Update: Genentech volatility flat at 29 into EPS (Blogging Stocks)

Jul 07 2008
Genentech - Ava$tin contd. (PharmaGossip)

Jul 07 2008
What Does It Mean To Say A Pricey Drug Works? (Pharmalot)

Jul 05 2008

Employees

Number of Employees: 11,174

Revenue per Employee: $1,113,073

Top Executives

Patrick Y. Yang, Ph.D., Divisional Executive VP

Richard H. Scheller, Ph.D., Divisional Executive VP

Dr. Hal Barron, M.D., F.A.C.C., Chief Medical Officer/Senior VP, Divisional

Robert L. Garnick, Ph.D., Divisional Senior VP

Ian T. Clark, Divisional Executive VP

Robert E. Andreatta, Chief Accounting Officer/Controller

Dr.Susan D. Desmond-Hellmann, M.D., M.P.H., Divisional President

John M. Whiting, Vice President, Divisional

Stephen G. Juelsgaard, D.V.M., J.D., Executive VP/Other Executive Officer/Secretary

Board of Directors

Dr. Jonathan K.C. Knowles, Ph.D., Director

Debra L. Reed, Director

Dr.Arthur D. Levinson, Ph.D., CEO/Chairman of the Board/Director

Dr.Herbert W. Boyer, Ph.D., Director/Founder

Dr. Erich Hunziker, Ph.D., Director

William Matt Burns, Director

Dr.Charles A. Sanders, M.D., Director

Financials

Quarterly

Annual

Income Statement	04/2008	01/2008	10/2007	07/2007
Sales	389 Mil.	344 Mil.	552 Mil.	597 Mil.
Gross Operating Profit	2.67 Bil.	2.63 Bil.	2.36 Bil.	2.41 Bil.
Operating Income before D & A (EBITDA)	1.54 Bil.	1.04 Bil.	1.2 Bil.	1.27 Bil.
Total Income Before Interest Expenses (EBIT)	1.28 Bil.	1.02 Bil.	1.15 Bil.	1.2 Bil.
Total Net Income	790 Mil.	632 Mil.	685 Mil.	747 Mil.
Basic EPS, Total	0.75	0.6	0.65	0.71
Diluted EPS, Total	0.74	0.59	0.64	0.7

BALANCE STATEMENT	04/2008	01/2008	10/2007	07/2007
Cash and Equivalents	4.86 Bil.	NA	1.7 Bil.	2.06 Bil.
Total Assets	NA	NA	6.67 Bil.	6.7 Bil.
Total Liabilities	3.97 Bil.	NA	2.06 Bil.	1.99 Bil.
Total Capitalization	15.37 Bil.	NA	13.98 Bil.	13.16 Bil.

Cash Flow	04/2008	01/2008	10/2007	07/2007
Net Cash From Continuing Operations	NA	NA	2.07 Bil.	1.42 Bil.
Net Cash From Investing Activities	NA	NA	-1.35 Bil.	-352 Mil.
Net Cash From Financing Activities	NA	NA	-274 Mil.	-263 Mil.
Net Change in Cash & Cash Equivalents	NA	NA	453 Mil.	810 Mil.

Income Statement	2008	2007	2006	2005
Sales	1.57 Bil.	774 Mil.	640.9 Mil.	319.3 Mil.
Gross Operating Profit	10.15 Bil.	8.51 Bil.	5.99 Bil.	3.66 Bil.
Operating Income before D & A (EBITDA)	4.37 Bil.	4.72 Bil.	2.47 Bil.	1.03 Bil.
Total Income Before Interest Expenses (EBIT)	4.5 Bil.	3.48 Bil.	2.06 Bil.	1.23 Bil.
Total Net Income	2.77 Bil.	2.11 Bil.	1.28 Bil.	784.82 Mil.
Basic EPS, Total	2.63	2.01	1.21	0.74
Diluted EPS, Total	2.59	1.97	1.18	0.73

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	NA	1.25 Bil.	1.23 Bil.	270.12 Mil.
Total Assets	NA	5.7 Bil.	4.42 Bil.	3.42 Bil.
Total Liabilities	NA	2.16 Bil.	1.66 Bil.	1.24 Bil.
Total Capitalization	NA	11.68 Bil.	9.55 Bil.	7.19 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	2.14 Bil.	2.36 Bil.	1.2 Bil.
Net Cash From Investing Activities	NA	-1.68 Bil.	-1.78 Bil.	-451.56 Mil.
Net Cash From Financing Activities	NA	-432 Mil.	367.53 Mil.	-846.31 Mil.
Net Change in Cash & Cash Equivalents	NA	25 Mil.	955.39 Mil.	-102.03 Mil.

Genentech Inc (DNA)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request